A detailed history of Kbc Group Nv transactions in Celldex Therapeutics, Inc. stock. As of the latest transaction made, Kbc Group Nv holds 3,728 shares of CLDX stock, worth $90,366. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,728
Previous 2,081 79.14%
Holding current value
$90,366
Previous $71,000 32.39%
% of portfolio
0.0%
Previous 0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 22, 2025

BUY
$23.31 - $32.4 $38,391 - $53,362
1,647 Added 79.14%
3,728 $94,000
Q3 2024

Nov 06, 2024

BUY
$32.06 - $44.56 $15,869 - $22,057
495 Added 31.21%
2,081 $71,000
Q1 2024

May 08, 2024

BUY
$35.22 - $51.88 $55,858 - $82,281
1,586 New
1,586 $67,000

Others Institutions Holding CLDX

About Celldex Therapeutics, Inc.


  • Ticker CLDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,772,400
  • Market Cap $1.13B
  • Description
  • Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-01...
More about CLDX
Track This Portfolio

Track Kbc Group Nv Portfolio

Follow Kbc Group Nv and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Kbc Group Nv, based on Form 13F filings with the SEC.

News

Stay updated on Kbc Group Nv with notifications on news.